Prevymis (letermovir) - Merck (MSD)
Triplex (CMV-MVA vaccine) - Fortress
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (clinicaltrials.gov) - Mar 28, 2026 - P1 | N=46 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2027 ➔ Feb 2030 | Trial primary completion date: Jun 2027 ➔ Feb 2030 
Enrollment open • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Non-Hodgkin's Lymphoma • Oncology • Transplantation • HLA-B • HLA-C • HLA-DPB1 • HLA-DQB1 • HLA-DRB1
http://clinicaltrials.gov/ct2/show/NCT07020533
 
Mar 28, 2026
 
Prev Next